CA1336410C - Products containing a calcium antagonist and a lipid-lowering agent - Google Patents
Products containing a calcium antagonist and a lipid-lowering agentInfo
- Publication number
- CA1336410C CA1336410C CA000592635A CA592635A CA1336410C CA 1336410 C CA1336410 C CA 1336410C CA 000592635 A CA000592635 A CA 000592635A CA 592635 A CA592635 A CA 592635A CA 1336410 C CA1336410 C CA 1336410C
- Authority
- CA
- Canada
- Prior art keywords
- lipid
- lowering agent
- acid
- calcium antagonist
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title claims abstract description 12
- 239000003524 antilipemic agent Substances 0.000 title claims abstract description 11
- 239000000480 calcium channel blocker Substances 0.000 title claims description 8
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 229960002297 fenofibrate Drugs 0.000 claims description 7
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 7
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical group C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229960001722 verapamil Drugs 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229960003501 etofibrate Drugs 0.000 description 2
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 229960000457 gallopamil Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960000881 verapamil hydrochloride Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RSMSFENOAKAUJU-UHFFFAOYSA-L bis[[2-(4-chlorophenoxy)-2-methylpropanoyl]oxy]aluminum;hydrate Chemical compound O.C=1C=C(Cl)C=CC=1OC(C)(C)C(=O)O[Al]OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 RSMSFENOAKAUJU-UHFFFAOYSA-L 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229960001767 dextrothyroxine Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004351 etafenone Drugs 0.000 description 1
- OEGDFSLNGABBKJ-UHFFFAOYSA-N etafenone Chemical compound CCN(CC)CCOC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 OEGDFSLNGABBKJ-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- LWZCMKGGFONJPB-UHFFFAOYSA-N etiroxate Chemical compound IC1=CC(CC(C)(N)C(=O)OCC)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 LWZCMKGGFONJPB-UHFFFAOYSA-N 0.000 description 1
- 229950010737 etiroxate Drugs 0.000 description 1
- 229950009036 etofylline clofibrate Drugs 0.000 description 1
- KYAKGJDISSNVPZ-UHFFFAOYSA-N etofylline clofibrate Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KYAKGJDISSNVPZ-UHFFFAOYSA-N 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- BCARVEADLDZBJT-HVDRVSQOSA-N magnesium pyridoxal 5-phosphate glutamate Chemical compound OC(=O)[C@@H](N)CCC(N)=O.CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O BCARVEADLDZBJT-HVDRVSQOSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960000989 perhexiline Drugs 0.000 description 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004855 xantinol nicotinate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Combinations of calcium antagonists and lipid-lowering agents are suitable for controlling diseases.
Description
O.Z. 0480/01047 Products containinq a calcium antagonist and a lipid-lowering aaent It i8 known that calcium antagonists are effec-tive drugs for the treatment of coronary heart disease (H. Eichstadt, Calcium-Antagonisten, Chapter 33 in Hand-buch der inneren Medizin, Volume IX/3: Roronarerkran-kungen, Editor H. Roskamm, Springer-Verlag, Berlin, 1984;
U. Borchard, Spektrum Roronartherapeutika, Aesopus Ver-lag, Zug, 1985).
10Furthermore, a number of lipid-lowering agents which can be used for the treatment of hyperlipidemia have been described (W. Rruse et al., Spektrum Lipid-senker, Aesopus Verlag, Zug, 1985). It is also known that fibrates improve the flow properties of the blood 15(eg. Ernst/Matrai, Therapiewoche 38 (1988), 136-139;
Lecture by Leschke at the experts' discussion Aktueller Stand der Therapie von Fettstoffwechselstorungen, WieshA~en, October 10 1987; Arzte-Zeitung 6 (1987), 29).
We have found that the action of calcium antagon-ists can be improved by adding lipid-lowering agents.
The present invention relates to products con-tAining a calcium antagonist and a lipid-lowering agent.
The products may be in the form of combination preparations for simultaneous use in a fixed combination or as separate components for use simultaneously or sequentially.
Particular examples of calcium antagonists are diltiazem, etafenone, fendiline, gallopamil, nifedipine, prenylamine, perhexiline and verapamil. Among these, verapamil and gallopamil are preferred.
Examples of suitable lipid-lowering agents are bezafibrate, clofibrate and aluminum clofibrate and etofylline clofibrate, colestipol, colestyramine, dex-trothyroxine, etiroxate, etofibrate, fenofibrate, gem-fibrozil, inositol nicotinate, magnesium pyridoxal 5'-phosphate glutamate, probucol, 3-pyridylmethanol, ~-sitosterol and xantinol nicotinate. Among these ~..~
U. Borchard, Spektrum Roronartherapeutika, Aesopus Ver-lag, Zug, 1985).
10Furthermore, a number of lipid-lowering agents which can be used for the treatment of hyperlipidemia have been described (W. Rruse et al., Spektrum Lipid-senker, Aesopus Verlag, Zug, 1985). It is also known that fibrates improve the flow properties of the blood 15(eg. Ernst/Matrai, Therapiewoche 38 (1988), 136-139;
Lecture by Leschke at the experts' discussion Aktueller Stand der Therapie von Fettstoffwechselstorungen, WieshA~en, October 10 1987; Arzte-Zeitung 6 (1987), 29).
We have found that the action of calcium antagon-ists can be improved by adding lipid-lowering agents.
The present invention relates to products con-tAining a calcium antagonist and a lipid-lowering agent.
The products may be in the form of combination preparations for simultaneous use in a fixed combination or as separate components for use simultaneously or sequentially.
Particular examples of calcium antagonists are diltiazem, etafenone, fendiline, gallopamil, nifedipine, prenylamine, perhexiline and verapamil. Among these, verapamil and gallopamil are preferred.
Examples of suitable lipid-lowering agents are bezafibrate, clofibrate and aluminum clofibrate and etofylline clofibrate, colestipol, colestyramine, dex-trothyroxine, etiroxate, etofibrate, fenofibrate, gem-fibrozil, inositol nicotinate, magnesium pyridoxal 5'-phosphate glutamate, probucol, 3-pyridylmethanol, ~-sitosterol and xantinol nicotinate. Among these ~..~
- 2 - O.Z. 0480/01047 substances, the fibrates (bezafibrate, clofibrate, eto-fibrate and fenofibrate) are preferred.
If the substances contain basic groups, they can also be used for the combination preparation in the form of their salts with physiologically tolerated acids.
Suitable and preferred physiologically tolerated acids are hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, malonic acid, salicylic acid, maleic acid, fumaric acid, succinic acid, ascorbic acid, malic acid, methAnesulfonic acid, lactic acid, gluconic acid, glucuronic acid, amidosulfonic acid, benzoic acid and tartaric acid.
The calcium antagonist and lipid-lowering agent are present in the mixture in amounts which are at the lower limit of the doses usually recommended for these substances, or somewhat below this limit. As a rule, the ratio of the amounts of lipid-lowering agent to calcium antagonist is from 10 : 1 to 1 : 10. For a combination of verapamil and fenofibrate, this ratio is preferably from 1 : 2 to 2 : 1.
The novel combination improves the flow proper-ties of the blood in an llneypected synergistic manner compared with the individual components of the combina-tion. It is therefore suitable for the therapy and prevention of symptoms due to distllrhA~ces of myocardial blood flow in coronary heart disease, ie. all angina pectoris form~, for the aftertreatment of myocardial infarction and for use before and after balloon angio-plasty and bypass operations.
The novel products can be administered parenter-ally but are preferably administered orally. Tablets, coated tablets and capsules are particularly suitable for oral administration. SustAine~-release forms are espec-ially suitable. The known processes, as described in, for example, H. Sucker et al., Pharmazeutische Tech-nologie, Thieme-Verlag, Stuttgart 1978, are suitable for the preparation of the stated forms. It is also possible - 3 - O.Z. 0480/01047 possible to convert the individual components of the mixture into administration forms and to pack these together, for example in a blister pack.
20 IsoptinORR sustAine~-release tablets and 20 NormalipO sustAin~-release capsules were introduced in pairs into each blister pack.
Pellets having the following composition were prepared:
a) fenofibrate 100.00 mg sucrose 17.92 mg corn starch 5.96 mg polyvidone 0.74 mg talc 1.49 mg polymethacrylic acid L 1.44 mg polymethacrylic acid E 0.40 mg stearic acid 0.05 mg 128.00 mg *~anufacturer: Rohm, Darmstadt b) verapamil hydrochloride 100.00 mg colloidal silica 1.00 mg corn starch 6.96 mg sugar pellets 22.65 mg ethylcellulose 3.40 mg glycerol mono-/dioleate 2.27 mg ~Eudragit RS 1.45 mg OEudragit S 2.90 mg dibutyl phthalate 0.29 mg talc 9.38 mg 150.30 mg Polymer of acrylates and methacrylates having a low content of quaternary ammonium groups (manu-facturer: Rohm, Darmstadt) - 4 - O.Z. 0480tO1047 Anionic polymer of methacrylic acid and meth-acrylates (manufacturer: Rohm, Darmstadt) 128.0 mg of pellets a) and 150.3 mg of pellets b) were introduced into each hard gelatine capsules.
Example 2 was repeated, except that 192.0 mg of pellet~ a) and 150.3 mg of pellets b) were introduced per hard gelatine capsule.
Example 2 was repeated, except that 128.0 mg of pellets a) and 300.6 mg of pellets b) were introduced per hard gelatine capsule.
Tablets having the following composition were compressed:
a) fenofibrate 80.00 sucrose 14.35 corn starch 4.77 polyvidone 0.59 talc 1.19 b) verapamil hydrochloride 80.00 colloidal silica 0.80 corn starch 5.60 sugar pellets 18.17 ethylcellulose 2.72 glycerol mono-/dioleate 1.81 talc 7.50 The tablets were introduced into capsules in the ratio of 1 : 1.
If the substances contain basic groups, they can also be used for the combination preparation in the form of their salts with physiologically tolerated acids.
Suitable and preferred physiologically tolerated acids are hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, malonic acid, salicylic acid, maleic acid, fumaric acid, succinic acid, ascorbic acid, malic acid, methAnesulfonic acid, lactic acid, gluconic acid, glucuronic acid, amidosulfonic acid, benzoic acid and tartaric acid.
The calcium antagonist and lipid-lowering agent are present in the mixture in amounts which are at the lower limit of the doses usually recommended for these substances, or somewhat below this limit. As a rule, the ratio of the amounts of lipid-lowering agent to calcium antagonist is from 10 : 1 to 1 : 10. For a combination of verapamil and fenofibrate, this ratio is preferably from 1 : 2 to 2 : 1.
The novel combination improves the flow proper-ties of the blood in an llneypected synergistic manner compared with the individual components of the combina-tion. It is therefore suitable for the therapy and prevention of symptoms due to distllrhA~ces of myocardial blood flow in coronary heart disease, ie. all angina pectoris form~, for the aftertreatment of myocardial infarction and for use before and after balloon angio-plasty and bypass operations.
The novel products can be administered parenter-ally but are preferably administered orally. Tablets, coated tablets and capsules are particularly suitable for oral administration. SustAine~-release forms are espec-ially suitable. The known processes, as described in, for example, H. Sucker et al., Pharmazeutische Tech-nologie, Thieme-Verlag, Stuttgart 1978, are suitable for the preparation of the stated forms. It is also possible - 3 - O.Z. 0480/01047 possible to convert the individual components of the mixture into administration forms and to pack these together, for example in a blister pack.
20 IsoptinORR sustAine~-release tablets and 20 NormalipO sustAin~-release capsules were introduced in pairs into each blister pack.
Pellets having the following composition were prepared:
a) fenofibrate 100.00 mg sucrose 17.92 mg corn starch 5.96 mg polyvidone 0.74 mg talc 1.49 mg polymethacrylic acid L 1.44 mg polymethacrylic acid E 0.40 mg stearic acid 0.05 mg 128.00 mg *~anufacturer: Rohm, Darmstadt b) verapamil hydrochloride 100.00 mg colloidal silica 1.00 mg corn starch 6.96 mg sugar pellets 22.65 mg ethylcellulose 3.40 mg glycerol mono-/dioleate 2.27 mg ~Eudragit RS 1.45 mg OEudragit S 2.90 mg dibutyl phthalate 0.29 mg talc 9.38 mg 150.30 mg Polymer of acrylates and methacrylates having a low content of quaternary ammonium groups (manu-facturer: Rohm, Darmstadt) - 4 - O.Z. 0480tO1047 Anionic polymer of methacrylic acid and meth-acrylates (manufacturer: Rohm, Darmstadt) 128.0 mg of pellets a) and 150.3 mg of pellets b) were introduced into each hard gelatine capsules.
Example 2 was repeated, except that 192.0 mg of pellet~ a) and 150.3 mg of pellets b) were introduced per hard gelatine capsule.
Example 2 was repeated, except that 128.0 mg of pellets a) and 300.6 mg of pellets b) were introduced per hard gelatine capsule.
Tablets having the following composition were compressed:
a) fenofibrate 80.00 sucrose 14.35 corn starch 4.77 polyvidone 0.59 talc 1.19 b) verapamil hydrochloride 80.00 colloidal silica 0.80 corn starch 5.60 sugar pellets 18.17 ethylcellulose 2.72 glycerol mono-/dioleate 1.81 talc 7.50 The tablets were introduced into capsules in the ratio of 1 : 1.
Claims (7)
1. A product containing a calcium antagonist and a lipid-lowering agent.
2. A product as claimed in claim 1, as a combination preparation for simultaneous use in a fixed combination or as separate components for use simultaneously or sequentially.
3. A product as claimed in claim 1, wherein the ratio of calcium antagonist to lipid-lowering agent is from 10 : 1 to 1 : 10.
4. A product as claimed in claim 1, wherein the calcium antagonist is verapamil and the lipid-lowering agent is fenofibrate.
5. A product as claimed in claim 4, wherein the ratio of verapamil to fenofibrate is from 1 : 2 to 2 : 1.
6. A product as claimed in claim 1, for use to control diseases.
7. Use of a product as claimed in claim 1 for the preparation of drugs for the treatment of coronary heart disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3807895A DE3807895A1 (en) | 1988-03-10 | 1988-03-10 | PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER |
| DEP3807895.3 | 1988-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1336410C true CA1336410C (en) | 1995-07-25 |
Family
ID=6349341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000592635A Expired - Fee Related CA1336410C (en) | 1988-03-10 | 1989-03-02 | Products containing a calcium antagonist and a lipid-lowering agent |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4925672A (en) |
| EP (1) | EP0332918B1 (en) |
| JP (1) | JPH01268647A (en) |
| AT (1) | ATE75407T1 (en) |
| CA (1) | CA1336410C (en) |
| DE (2) | DE3807895A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4016963A1 (en) * | 1990-05-25 | 1991-11-28 | Steigerwald Arzneimittelwerk | USE OF MAGNESIUM PYRIDOXAL 5'-PHOSPHATE GLUTAMINATE TO PREVENT ILLNESSES ARISING AS A RESULT OF DISSOLUTION |
| US5252337A (en) * | 1991-06-25 | 1993-10-12 | Eurand America, Inc. | Controlled release calcium channel blocker microcapsules |
| DE19608750A1 (en) * | 1996-03-06 | 1997-09-11 | Durachemie Gmbh & Co Kg | Process for the production of fenofibrate preparations |
| FR2758459B1 (en) * | 1997-01-17 | 1999-05-07 | Pharma Pass | FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
| GT199800127A (en) * | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. | |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6982281B1 (en) * | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| IT1317885B1 (en) * | 2000-08-01 | 2003-07-15 | Sigma Tau Ind Farmaceuti | USE OF FIBRATES FOR THE PREPARATION OF A USEFUL DRUG IN THE TREATMENT OF CONGESTIAL HEART INSUFFICIENCY. |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| JP2004517920A (en) * | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | Combination of sterol absorption inhibitors and blood conditioning agents to treat vascular conditions |
| US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
| US7071181B2 (en) * | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| PT1413331E (en) * | 2001-01-26 | 2007-12-18 | Schering Corp | Combinations of the peroxisome proliferator-activated receptor (ppar) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications |
| IL156422A0 (en) * | 2001-01-26 | 2004-01-04 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| BR0206644A (en) * | 2001-01-26 | 2004-02-25 | Schering Corp | Sterol absorption inhibitor (s) combinations with cardiovascular agent (s) for the treatment of vascular conditions |
| AU2002241956A1 (en) * | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| JP2004517916A (en) * | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | Combination of nicotinic acid and its derivatives and sterol absorption inhibitors, and treatment of vascular indications |
| AU2002308778A1 (en) * | 2001-05-25 | 2002-12-09 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| ATE345793T1 (en) * | 2001-09-21 | 2006-12-15 | Schering Corp | TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS |
| US7056906B2 (en) * | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US20030119808A1 (en) * | 2001-09-21 | 2003-06-26 | Schering Corporation | Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects |
| WO2003026644A1 (en) * | 2001-09-21 | 2003-04-03 | Schering Corporation | Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US20040005359A1 (en) * | 2002-06-27 | 2004-01-08 | Cheng Xiu Xiu | Controlled release oral dosage form |
| WO2004043456A1 (en) * | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| EP1606287B1 (en) | 2003-03-07 | 2013-10-02 | Merck Sharp & Dohme Corp. | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| JP2007510659A (en) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | Combinations of lipid modulators and substituted azetidinones and treatment of vascular conditions |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| JP2020503269A (en) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | Oral testosterone undecanoate therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3247118A1 (en) * | 1982-12-20 | 1984-06-20 | Cassella Ag, 6000 Frankfurt | NEW SUBSTITUTED 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT |
| CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
| DE3612212A1 (en) * | 1986-04-11 | 1987-10-15 | Basf Ag | METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS |
-
1988
- 1988-03-10 DE DE3807895A patent/DE3807895A1/en not_active Withdrawn
-
1989
- 1989-02-28 AT AT89103451T patent/ATE75407T1/en not_active IP Right Cessation
- 1989-02-28 DE DE8989103451T patent/DE58901259D1/en not_active Expired - Lifetime
- 1989-02-28 EP EP89103451A patent/EP0332918B1/en not_active Expired - Lifetime
- 1989-03-02 CA CA000592635A patent/CA1336410C/en not_active Expired - Fee Related
- 1989-03-06 US US07/318,825 patent/US4925672A/en not_active Expired - Fee Related
- 1989-03-07 JP JP1053064A patent/JPH01268647A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH01268647A (en) | 1989-10-26 |
| DE3807895A1 (en) | 1989-09-21 |
| EP0332918A2 (en) | 1989-09-20 |
| DE58901259D1 (en) | 1992-06-04 |
| US4925672A (en) | 1990-05-15 |
| EP0332918B1 (en) | 1992-04-29 |
| ATE75407T1 (en) | 1992-05-15 |
| EP0332918A3 (en) | 1989-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1336410C (en) | Products containing a calcium antagonist and a lipid-lowering agent | |
| JP4108980B2 (en) | Sustained release ranolazine formulation | |
| US8987333B2 (en) | Composition and method for treating neurological disease | |
| RU2214233C2 (en) | Ranolazine preparations with prolonged effect | |
| US5296232A (en) | Pharmaceutical formulation which does not induce tolerance | |
| US20070270443A1 (en) | Methods and compositions for the treatment of viral infections | |
| JP2008069159A5 (en) | ||
| US20220211641A1 (en) | Composition and method for treating neurological disease | |
| Scheidt et al. | Nicardipine for stable angina pectoris. | |
| JPS6293230A (en) | Combined medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |